MA52486A - Pyridazinones utilisés en tant qu'inhibiteurs de parp7 - Google Patents

Pyridazinones utilisés en tant qu'inhibiteurs de parp7

Info

Publication number: MA52486A
Authority: MA; Morocco
Prior art keywords: pyridazinones; parp7; inhibitors; parp7 inhibitors; pyridazinones used
Prior art date: 2018-04-30

Application number

MA052486A

Other languages

English (en)

Other versions

MA52486B1 (fr

Inventor

Kevin Wayne Kuntz

Laurie B Schenkel

Kerren Kalai Swinger

Melissa Marie Vasbinder

Original Assignee

Ribon Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-04-30

Filing date

2019-04-29

Publication date

2021-03-10

2019-04-29 Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc

2021-03-10 Publication of MA52486A publication Critical patent/MA52486A/fr

2023-04-28 Publication of MA52486B1 publication Critical patent/MA52486B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA52486A 2018-04-30 2019-04-29 Pyridazinones utilisés en tant qu'inhibiteurs de parp7 MA52486B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862664544P	2018-04-30	2018-04-30
PCT/US2019/029582 WO2019212937A1 (fr)	2018-04-30	2019-04-29	Pyridazinones utilisés en tant qu'inhibiteurs de parp7

Publications (2)

Publication Number	Publication Date
MA52486A true MA52486A (fr)	2021-03-10
MA52486B1 MA52486B1 (fr)	2023-04-28

Family

ID=66476851

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA52486A MA52486B1 (fr)	2018-04-30	2019-04-29	Pyridazinones utilisés en tant qu'inhibiteurs de parp7

Country Status (36)

Country	Link
US (6)	US10550105B2 (fr)
EP (2)	EP4234551A3 (fr)
JP (2)	JP6942896B2 (fr)
KR (1)	KR102862474B1 (fr)
CN (2)	CN112424188B (fr)
AR (1)	AR121419A1 (fr)
AU (2)	AU2019262927B2 (fr)
BR (1)	BR112020022006A2 (fr)
CA (1)	CA3098585A1 (fr)
CL (1)	CL2020002821A1 (fr)
CO (1)	CO2020013599A2 (fr)
CR (1)	CR20200518A (fr)
CY (1)	CY1126132T1 (fr)
DK (1)	DK3788040T3 (fr)
EA (1)	EA202092590A1 (fr)
EC (1)	ECSP20069404A (fr)
ES (1)	ES2949538T3 (fr)
FI (1)	FI3788040T3 (fr)
HR (1)	HRP20230458T1 (fr)
HU (1)	HUE062096T2 (fr)
IL (2)	IL308983B2 (fr)
LT (1)	LT3788040T (fr)
MA (1)	MA52486B1 (fr)
MD (1)	MD3788040T2 (fr)
MX (2)	MX2020011465A (fr)
PE (1)	PE20211382A1 (fr)
PH (1)	PH12020551760A1 (fr)
PL (1)	PL3788040T3 (fr)
PT (1)	PT3788040T (fr)
RS (1)	RS64283B1 (fr)
SG (1)	SG11202010183XA (fr)
SI (1)	SI3788040T1 (fr)
SM (1)	SMT202300172T1 (fr)
TW (2)	TWI877697B (fr)
WO (1)	WO2019212937A1 (fr)
ZA (1)	ZA202006549B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019212946A1 (fr)	2018-04-30	2019-11-07	Ribon Therapeutics Inc.	Procédés de criblage de modulateurs parp
EA202092590A1 (ru) *	2018-04-30	2021-04-08	Рибон Терапьютикс Инк.	Пиридазиноны в качестве ингибиторов parp7
WO2019241131A1 (fr)	2018-06-11	2019-12-19	Pipeline Therapeutics, Inc.	Antagonistes des récepteurs muscariniques de l'acétylcholine m1
EP3846806A4 (fr)	2018-09-04	2022-06-08	Pipeline Therapeutics, Inc.	Antagonistes du récepteur m1 de l'acétylcholine muscarinique
WO2020191056A1 (fr) *	2019-03-20	2020-09-24	Goldfinch Bio, Inc.	Pyridazinones et leurs procédés d'utilisation
WO2020223229A1 (fr) *	2019-04-29	2020-11-05	Ribon Therapeutics, Inc.	Formes solides d'un inhibiteur de parp7
CN121378271A (zh) *	2019-10-07	2026-01-23	康蒂内乌姆医疗公司	毒蕈碱型乙酰胆碱m1受体拮抗剂
KR20220109401A (ko) *	2019-10-30	2022-08-04	리본 테라퓨틱스 인코포레이티드	Parp7 억제제로서의 피리다진온
US20240190844A1 (en) *	2019-10-30	2024-06-13	Ribon Therapeutics, Inc.	Pyridazinones as parp7 inhibitors
US11752149B2 (en)	2019-12-02	2023-09-12	Pipeline Therapeutics, Inc.	Muscarinic acetylcholine M1 receptor antagonists
AU2021261383A1 (en) *	2020-04-23	2022-11-17	Opna Bio SA	Compounds and methods for CD73 modulation and indications therefor
US20230219942A1 (en) *	2020-06-09	2023-07-13	Relive Therapeutics Inc.	Compounds comprising a three ring core as pd-1/pd-l1 blockers
AU2021302090B2 (en) *	2020-07-03	2024-01-18	Wuhan Ll Science And Technology Development Co., Ltd.	Heterocyclic compound and use thereof
WO2022111700A1 (fr) *	2020-11-27	2022-06-02	成都百裕制药股份有限公司	Dérivés de pyridazinone et leur utilisation en médecine
JP7623826B2 (ja) *	2020-12-18	2025-01-29	株式会社資生堂	Ｔｉｐａｒｐ産生促進剤
WO2022156708A1 (fr) *	2021-01-20	2022-07-28	Jacobio Pharmaceuticals Co., Ltd.	Inhibiteur d'enzyme parp7
CN116724044B (zh) *	2021-02-03	2025-10-31	上海湃隆生物科技有限公司	三并杂环类化合物、其制备方法及其应用
TWI824403B (zh) *	2021-02-07	2023-12-01	大陸商武漢朗來科技發展有限公司	一種雜環化合物、其中間體、其製備方法及其應用
WO2022170974A1 (fr) *	2021-02-09	2022-08-18	Jacobio Pharmaceuticals Co., Ltd.	Dérivés tricycliques utiles en tant qu'inhibiteurs de parp7
WO2022177877A1 (fr)	2021-02-16	2022-08-25	Ribon Therapeutics, Inc.	Schémas posologiques pour inhibiteurs de parp7
CN115028648B (zh) *	2021-03-03	2024-08-30	武汉誉祥医药科技有限公司	三并环化合物及其药物组合物和应用
CN117425648A (zh) *	2021-03-12	2024-01-19	杭州英创医药科技有限公司	作为parp7抑制剂的化合物
CA3212319A1 (fr) *	2021-03-16	2022-09-22	Hualing XIAO	Compose heterocyclique polycyclique contenant de l'azote, son procede de preparation et son utilisation
JP7768592B2 (ja) *	2021-03-31	2025-11-12	デュークストリートバイオリミテッド	医薬化合物
GB202114315D0 (en) *	2021-10-06	2021-11-17	Duke Street Bio Ltd	Pharmaceutical compound
WO2022223022A1 (fr) *	2021-04-23	2022-10-27	四川海思科制药有限公司	Dérivé hétérocyclique à cycles fusionnés et son application médicale
CA3217941A1 (fr) *	2021-05-21	2022-11-24	Chengdu Baiyu Pharmaceutical Co., Ltd.	Derive de piperazine et son utilisation en medecine
WO2022247839A1 (fr) *	2021-05-25	2022-12-01	山东轩竹医药科技有限公司	Inhibiteur de parp7
CN115477640A (zh) *	2021-05-31	2022-12-16	由理生物医药（上海）有限公司	作为parp7抑制剂的哒嗪酮类化合物
CN117751108A (zh) *	2021-07-21	2024-03-22	南京明德新药研发有限公司	哒嗪酮类化合物
WO2023001296A1 (fr) *	2021-07-23	2023-01-26	武汉人福创新药物研发中心有限公司	Composé de pyridazinone utile en tant qu'inhibiteur de parp7
CN117279907A (zh) *	2021-08-06	2023-12-22	成都百裕制药股份有限公司	吡咯烷酮衍生物及其在医药上的应用
WO2023020479A1 (fr) *	2021-08-16	2023-02-23	重庆华森制药股份有限公司	Inhibiteur de parp7 et son application
EP4387966A4 (fr) *	2021-08-17	2026-02-11	Inventisbio Co Ltd	Composés de pyridazinone ou pyridinone, leurs procédés de préparation et leurs utilisations
JP2024539252A (ja)	2021-10-28	2024-10-28	ギリアードサイエンシーズ，インコーポレイテッド	ピリジジン－３（２ｈ）－オン誘導体
CN115745971B (zh) *	2021-12-20	2024-07-30	北京华森英诺生物科技有限公司	Parp7抑制剂及其应用
CN116375688B (zh) *	2021-12-23	2025-04-11	中国药科大学	哒嗪酮类化合物及其制备方法、药物组合物和应用
CN116444497B (zh) *	2022-01-14	2025-06-24	如东凌达生物医药科技有限公司	一类哒嗪酮类化合物、制备及其应用
CN116535395B (zh) *	2022-01-26	2024-07-09	中国药科大学	2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
WO2023143236A1 (fr) *	2022-01-26	2023-08-03	中国药科大学	Composé de 2h-indazole-7-formamide, procédé de préparation, composition pharmaceutique, et application
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
JP7763538B2 (ja) *	2022-04-01	2025-11-04	諾沃斯達薬業（上海）有限公司	Ｐａｒｐ７阻害剤及びその使用
TW202346294A (zh) *	2022-04-21	2023-12-01	大陸商四川海思科製藥有限公司	吡嗪酮衍生物及其在醫藥上的應用
CN117586263A (zh) *	2022-08-09	2024-02-23	成都百裕制药股份有限公司	哌嗪衍生物及其在医药上的应用
CN119584968A (zh) *	2022-08-09	2025-03-07	康百达（四川）生物医药科技有限公司	哌嗪类化合物在联合放疗治疗肿瘤中的用途
KR20250044423A (ko) *	2022-08-09	2025-03-31	캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디.	피페라진 화합물과 pd-1 억제제 또는 pd-l1 억제제의 조성물 및 종양 치료에 있어서의 그의 용도
UY40397A (es) *	2022-08-17	2024-03-15	Jacobio Pharmaceuticals Co Ltd	Formas sólidas del compuesto i o sales de las mismas
GB202213819D0 (en)	2022-09-22	2022-11-09	Duke Street Bio Ltd	Pharmaceutical compound
CN115490671B (zh) *	2022-10-21	2024-05-14	水木未来(北京)科技有限公司	Parp7抑制剂及其制备方法
CN117551080A (zh) *	2022-11-11	2024-02-13	杭州师范大学	一种靶向降解parp7的protac化合物及其制备方法与应用
CN118027039A (zh) *	2022-11-14	2024-05-14	成都百裕制药股份有限公司	一种取代的哌嗪衍生物的晶体及其制备方法
GB202217888D0 (en)	2022-11-29	2023-01-11	Duke Street Bio Ltd	Pharmaceutical compound
WO2024146631A1 (fr) *	2023-01-06	2024-07-11	齐鲁制药有限公司	Procédé de préparation d'inhibiteur de parp7
WO2024149234A1 (fr) *	2023-01-10	2024-07-18	Angel Pharmaceutical Co., Ltd.	Inhibiteurs de parp7 et leurs utilisations
WO2024149231A1 (fr) *	2023-01-10	2024-07-18	Angel Pharmaceutical Co., Ltd.	Inhibiteurs de parp7 et leurs utilisations
CN118388414A (zh) *	2023-01-17	2024-07-26	中国药科大学	哒嗪酮类化合物及其制备方法、药物组合物和应用
WO2025036478A1 (fr) *	2023-08-17	2025-02-20	康百达（四川）生物医药科技有限公司	Préparation pharmaceutique de dérivé de pipérazine, son procédé de préparation et son utilisation
WO2025045134A1 (fr) *	2023-08-29	2025-03-06	康百达（四川）生物医药科技有限公司	Procédé de préparation et intermédiaire de dérivé de pipérazine
WO2025087383A1 (fr) *	2023-10-26	2025-05-01	深圳众格生物科技有限公司	Composé agissant en tant qu'inhibiteur de parp7
TW202519233A (zh) *	2023-11-13	2025-05-16	大陸商康百達（四川）生物醫藥科技有限公司	一種parp7抑制劑聯合用藥的藥物組合及其治療腫瘤的用途
CN117342983B (zh) *	2023-12-05	2024-02-06	康羽生命科学技术(苏州)有限公司	过乙酰化GalNAc-L96合成方法
WO2025209574A1 (fr) *	2024-04-03	2025-10-09	康百达（四川）生物医药科技有限公司	Inhibiteur de parp7 pour la prévention ou le traitement de tumeurs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1157602C (zh)	1997-09-05	2004-07-14	松下电器产业株式会社	荧光偏振法检测样品的方法及其中使用的试剂
WO2002082082A2 (fr)	2001-04-09	2002-10-17	Boehringer Ingelheim Pharmaceuticals, Inc.	Analyse par polarisation de fluorescence
HU227237B1 (en)	2001-09-27	2010-12-28	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en)	2002-09-19	2003-02-26	Aventis Pharma Inc	Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
KR101286969B1 (ko) *	2004-06-30	2013-07-23	얀센 파마슈티카 엔.브이.	Ｐａｒｐ 저해제로서의 퀴나졸리논 유도체
GB0610680D0 (en) *	2006-05-31	2006-07-12	Istituto Di Ricerche D Biolog	Therapeutic compounds
RS52626B (sr)	2006-07-25	2013-06-28	Cephalon Inc.	Derivati piridizinona
MX2010005070A (es) *	2007-11-15	2010-05-24	Angeletti P Ist Richerche Bio	Derivados de piridazinona como inhibidores de parp.
RU2490260C2 (ru) *	2008-03-27	2013-08-20	Янссен Фармацевтика Нв	Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
CA2771190C (fr) *	2009-08-17	2020-01-21	Memorial Sloan-Kettering Cancer Center	Composes de liaison a une proteine de choc thermique, compositions et procedes pour les fabriquer et les utiliser
CN103570725B (zh) *	2012-08-01	2017-03-22	中国科学院上海药物研究所	哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2970289A1 (fr) *	2013-03-15	2016-01-20	Vertex Pharmaceuticals Inc.	Composés utiles en tant qu'inhibiteurs de la kinase atr
WO2016116602A1 (fr) *	2015-01-23	2016-07-28	Astrazeneca Ab	Traitement du cancer
CN106749261A (zh) *	2015-11-23	2017-05-31	中国科学院上海药物研究所	一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh)	2017-03-28	2022-12-01	美商富曼西公司	新穎噠嗪酮類除草劑
CA3075727A1 (fr) *	2017-09-18	2019-03-21	Goldfinch Bio, Inc.	Pyridazinones et leurs procedes d'utilisation
GB201717080D0 (en)	2017-10-18	2017-11-29	Syngenta Participations Ag	Chemical process
WO2019212946A1 (fr)	2018-04-30	2019-11-07	Ribon Therapeutics Inc.	Procédés de criblage de modulateurs parp
EA202092590A1 (ru)	2018-04-30	2021-04-08	Рибон Терапьютикс Инк.	Пиридазиноны в качестве ингибиторов parp7
WO2020223229A1 (fr)	2019-04-29	2020-11-05	Ribon Therapeutics, Inc.	Formes solides d'un inhibiteur de parp7
KR20220109401A (ko)	2019-10-30	2022-08-04	리본 테라퓨틱스 인코포레이티드	Parp7 억제제로서의 피리다진온
US20240190844A1 (en)	2019-10-30	2024-06-13	Ribon Therapeutics, Inc.	Pyridazinones as parp7 inhibitors

2019
- 2019-04-29 EA EA202092590A patent/EA202092590A1/ru unknown
- 2019-04-29 FI FIEP19723272.1T patent/FI3788040T3/fi active
- 2019-04-29 SI SI201930544T patent/SI3788040T1/sl unknown
- 2019-04-29 WO PCT/US2019/029582 patent/WO2019212937A1/fr not_active Ceased
- 2019-04-29 HU HUE19723272A patent/HUE062096T2/hu unknown
- 2019-04-29 SM SM20230172T patent/SMT202300172T1/it unknown
- 2019-04-29 TW TW112127538A patent/TWI877697B/zh active
- 2019-04-29 TW TW108114978A patent/TWI811353B/zh active
- 2019-04-29 IL IL308983A patent/IL308983B2/en unknown
- 2019-04-29 PE PE2020001749A patent/PE20211382A1/es unknown
- 2019-04-29 DK DK19723272.1T patent/DK3788040T3/da active
- 2019-04-29 BR BR112020022006-0A patent/BR112020022006A2/pt unknown
- 2019-04-29 SG SG11202010183XA patent/SG11202010183XA/en unknown
- 2019-04-29 AU AU2019262927A patent/AU2019262927B2/en active Active
- 2019-04-29 EP EP23161423.1A patent/EP4234551A3/fr active Pending
- 2019-04-29 KR KR1020207034323A patent/KR102862474B1/ko active Active
- 2019-04-29 PT PT197232721T patent/PT3788040T/pt unknown
- 2019-04-29 CA CA3098585A patent/CA3098585A1/fr active Pending
- 2019-04-29 RS RS20230450A patent/RS64283B1/sr unknown
- 2019-04-29 US US16/397,103 patent/US10550105B2/en active Active
- 2019-04-29 IL IL278116A patent/IL278116B2/en unknown
- 2019-04-29 MA MA52486A patent/MA52486B1/fr unknown
- 2019-04-29 PL PL19723272.1T patent/PL3788040T3/pl unknown
- 2019-04-29 MD MDE20210210T patent/MD3788040T2/ro unknown
- 2019-04-29 CR CR20200518A patent/CR20200518A/es unknown
- 2019-04-29 HR HRP20230458TT patent/HRP20230458T1/hr unknown
- 2019-04-29 CN CN201980044076.5A patent/CN112424188B/zh active Active
- 2019-04-29 AR ARP190101124A patent/AR121419A1/es unknown
- 2019-04-29 LT LTEPPCT/US2019/029582T patent/LT3788040T/lt unknown
- 2019-04-29 ES ES19723272T patent/ES2949538T3/es active Active
- 2019-04-29 EP EP19723272.1A patent/EP3788040B1/fr active Active
- 2019-04-29 JP JP2020560916A patent/JP6942896B2/ja active Active
- 2019-04-29 CN CN202510769671.2A patent/CN120987912A/zh active Pending
- 2019-04-29 MX MX2020011465A patent/MX2020011465A/es unknown
- 2019-10-24 US US16/662,409 patent/US10870641B2/en active Active
2020
- 2020-08-11 US US16/990,677 patent/US11014913B2/en active Active
- 2020-10-21 ZA ZA2020/06549A patent/ZA202006549B/en unknown
- 2020-10-22 PH PH12020551760A patent/PH12020551760A1/en unknown
- 2020-10-29 MX MX2023005804A patent/MX2023005804A/es unknown
- 2020-10-29 CL CL2020002821A patent/CL2020002821A1/es unknown
- 2020-10-29 EC ECSENADI202069404A patent/ECSP20069404A/es unknown
- 2020-10-29 CO CONC2020/0013599A patent/CO2020013599A2/es unknown
2021
- 2021-04-12 US US17/227,705 patent/US11566020B1/en active Active
- 2021-09-08 JP JP2021145986A patent/JP7518049B2/ja active Active
2022
- 2022-10-27 US US17/974,830 patent/US20230192664A1/en not_active Abandoned
2023
- 2023-07-03 CY CY20231100310T patent/CY1126132T1/el unknown
2024
- 2024-01-30 AU AU2024200566A patent/AU2024200566B2/en active Active
- 2024-03-22 US US18/613,601 patent/US20250034120A1/en active Pending

Also Published As

Publication number	Publication date
MD3788040T2 (ro)	2023-10-31
JP6942896B2 (ja)	2021-09-29
IL278116B1 (en)	2023-12-01
EP3788040B1 (fr)	2023-04-12
TWI811353B (zh)	2023-08-11
TW202344505A (zh)	2023-11-16
JP2021523104A (ja)	2021-09-02
PE20211382A1 (es)	2021-07-27
CR20200518A (es)	2021-03-22
KR20210014108A (ko)	2021-02-08
CA3098585A1 (fr)	2019-11-07
SG11202010183XA (en)	2020-11-27
IL278116A (en)	2020-11-30
US20200123134A1 (en)	2020-04-23
CN112424188B (zh)	2025-06-27
EA202092590A1 (ru)	2021-04-08
CO2020013599A2 (es)	2020-12-21
FI3788040T3 (fi)	2023-06-13
ECSP20069404A (es)	2021-01-29
PL3788040T3 (pl)	2023-08-07
KR102862474B1 (ko)	2025-09-24
CL2020002821A1 (es)	2021-02-19
SMT202300172T1 (it)	2023-09-06
CN120987912A (zh)	2025-11-21
JP7518049B2 (ja)	2024-07-17
ZA202006549B (en)	2025-06-25
ES2949538T3 (es)	2023-09-29
US20250034120A1 (en)	2025-01-30
MX2023005804A (es)	2023-05-29
AU2019262927B2 (en)	2023-11-02
EP4234551A3 (fr)	2023-10-11
CY1126132T1 (el)	2023-11-15
MA52486B1 (fr)	2023-04-28
LT3788040T (lt)	2023-06-26
PT3788040T (pt)	2023-07-12
US11566020B1 (en)	2023-01-31
TW202014416A (zh)	2020-04-16
US10870641B2 (en)	2020-12-22
HRP20230458T1 (hr)	2023-07-21
IL308983A (en)	2024-01-01
PH12020551760A1 (en)	2021-06-28
RS64283B1 (sr)	2023-07-31
SI3788040T1 (sl)	2023-07-31
JP2022017221A (ja)	2022-01-25
US20190330194A1 (en)	2019-10-31
CN112424188A (zh)	2021-02-26
IL308983B2 (en)	2025-10-01
AU2024200566A1 (en)	2024-02-15
US10550105B2 (en)	2020-02-04
HUE062096T2 (hu)	2023-09-28
MX2020011465A (es)	2020-12-07
US20230192664A1 (en)	2023-06-22
BR112020022006A2 (pt)	2021-01-26
AU2024200566B2 (en)	2026-03-05
IL278116B2 (en)	2024-04-01
EP4234551A2 (fr)	2023-08-30
US20210024502A1 (en)	2021-01-28
AR121419A1 (es)	2022-06-08
DK3788040T3 (da)	2023-05-08
WO2019212937A1 (fr)	2019-11-07
TWI877697B (zh)	2025-03-21
IL308983B1 (en)	2025-06-01
US11014913B2 (en)	2021-05-25
EP3788040A1 (fr)	2021-03-10
AU2019262927A1 (en)	2020-11-12

Publication	Publication Date	Title
MA52486A (fr)	2021-03-10	Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54076A (fr)	2022-02-09	2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr)	2022-10-26	2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA49566A (fr)	2020-05-20	Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA47460A (fr)	2019-12-18	Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA49888A (fr)	2020-06-24	Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA47013A (fr)	2018-08-29	Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51438A (fr)	2021-04-14	Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA51616A (fr)	2020-11-25	Inhibiteurs d'adn-pk
MA48994A (fr)	2020-02-05	Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
EP3906029A4 (fr)	2022-09-21	Inhibiteurs de l'interaction ménine-mll
MA42659A (fr)	2018-06-27	Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA43862A (fr)	2021-06-02	Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
EP3768661A4 (fr)	2021-12-22	Composés deutérés utilisés en tant qu'inhibiteurs de rock
MA41551A (fr)	2017-12-26	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA49374A (fr)	2021-04-21	Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA48803A (fr)	2020-04-08	Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA51429A (fr)	2021-04-07	Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
EP3733673A4 (fr)	2021-06-09	Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA45377A (fr)	2019-04-24	Composés hétérocycliques en tant qu'agents antibacteriens
MA42919A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA45375A (fr)	2019-04-24	Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA42918A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA54567A (fr)	2021-10-27	Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma